News Ultragenyx Announces Orphan Drug Designation for UX701 for the Treatment of Wilson Disease Jan 24, 2021 Posted by Ultragenyx
News Ultragenyx and Solid Biosciences Announce Strategic Collaboration to Develop and Commercialize New Gene Therapies for Duchenne Muscular Dystrophy Jan 24, 2021 Posted by Ultragenyx
News Ultragenyx Announces Positive Data from Confirmatory Cohort of Phase 1/2 Study of DTX401 Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa) Jan 24, 2021 Posted by Ultragenyx
News Ultragenyx Announces Positive Longer-term Results from First Three Cohorts of Phase 1/2 Study of DTX301 Gene Therapy in Ornithine Transcarbamylase (OTC) Deficiency Jan 24, 2021 Posted by Ultragenyx
News Ultragenyx Enters into Strategic Partnership with Daiichi Sankyo for Gene Therapy Manufacturing Technology Jan 24, 2021 Posted by Ultragenyx
News Ultragenyx Announces Positive Topline Cohort 3 Results and Improved Longer-Term Cohort 2 Results from Phase 1/2 Study of DTX301 Gene Therapy in Ornithine Transcarbamylase (OTC) Deficiency Jan 24, 2021 Posted by Ultragenyx
News CONTINUUS Pharmaceuticals Secures $69.3 Million Government Contract to Manufacture Critical Medicines in the U.S. Jan 22, 2021 Posted by CONTINUUS Pharmaceuticals, Inc.
News Expanded Global Oncology, Functional and Resourcing Services Launched by Catalyst Clinical Research Jan 19, 2021
News Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed in Phase 1/2 Study of TP-0184 for the Treatment of Anemia in Patients with Low or Intermediate Risk Myelodysplastic Syndromes Jan 19, 2021 Posted by Sumitomo Pharma Oncology, Inc.
